PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Following Positive Communication with the FDA , Regulatory Pathway Clarified for D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient Recruitment in Q2 20 23 into Ongoing SHIELD II Trial, w hich w ill b e Enriched with Approximately